ustekinumab
Phase 3- Indications
- Psoriasis
Company intelligence / Profile preview
STgen Bio operates as a contract development and manufacturing organization specializing in mammalian cell culture-based therapeutic proteins and monoclonal antibodies. The company has cGMP-approved facilities and supports global biopharmaceutical production, including the manufacture of biosimilars such as DMB‑3115 for psoriasis. They provide integrated services from drug substance to drug product manufacturing, packaging, and regulatory support.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on STgen Bio.